Opendata, web and dolomites

EXACT-dna SIGNED

EXtended Analysis of Circulating Tumour DNA to improve cancer management strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EXACT-dna project word cloud

Explore the words cloud of the EXACT-dna project. It provides you a very rough idea of what is the project "EXACT-dna" about.

through    sales    market    pending    confirming    validation    model    exquisitely    advantage    advantages    rearrangements    biopsy    genotyping    magazine    invasive    disrupt    biomarkers    proprietary    form    ready    commercialize    kits    superiority    liquid    sequence    meet    fold    days    quantification    variants    2020    exact    circulating    samples    saga    performance    verified    intends    dx    ibsafe    superior    patent    sensitivity    whereas    tumour    5000    time    free    technologies    detection    sensitive    gene    primary    healthcare    blood    dna    minimally    competitors    commercially    kroma    weeks    body    business    revolutionary    lower    services    fluids    opportunity    isolation    generating    patient    trade    ctdna    validate    revenue    chromosomal    applicability    map    mutations    competing    feasibility    clinically    technically    play    biopsies    road    overwhelming    global    improvement    validating    laboratory    turn    rna    faster    diagnostics    significantly    monitoring    clinical    cell    strategy    cancer    diagnostic    continued    forbes   

Project "EXACT-dna" data sheet

The following table provides information about the project.

Coordinator
SAGA DIAGNOSTICS AB 

Organization address
address: SCHEELEVAGEN 2, MV-401
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://sagadiagnostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SAGA DIAGNOSTICS AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

Through the EXACT-dna project, SAGA Diagnostics (SAGA Dx), intends to clinically validate and commercialize two distinct technologies, IBSAFE and KROMA, for the isolation, detection and quantification of cell-free circulating tumour DNA (ctDNA) in minimally invasive “liquid biopsies”. This revolutionary form of tumour genotyping and patient monitoring, based on the analysis of ctDNA and other tumour-specific biomarkers in body fluids such as blood samples, is one of five technologies that will disrupt healthcare by 2020 according to Forbes Magazine. SAGA Dx intends to take advantage of this business opportunity by further clinically validating their proprietary technologies which already have overwhelming superiority over competing methods due to four commercially- and technically-verified advantages that meet users’ needs: superior performance (a 100 to 5000-fold improvement in sensitivity), a faster turn-around time of 2-3 days (whereas competitors take 2-3 weeks), significantly lower production costs and wide applicability.

IBSAFE™ is a patent-pending technology for exquisitely sensitive and specific quantification of gene mutations and other sequence variants in any DNA or RNA sample. KROMA™, on the other hand, is a proprietary technology for the detection and quantification of tumour-specific chromosomal rearrangements in circulating tumour DNA.

SAGA Dx’s business model is based on generating revenue from the sales of laboratory services and ready-for-use diagnostic kits which are the primary focus of the Phase 2 project. The Phase 1 project will support this strategy by confirming the market feasibility of our technologies and define a road map for their continued clinical validation. The EXACT –dna project will play a significant role in strengthening the European presence in the rapidly growing global cancer liquid biopsy market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXACT-DNA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXACT-DNA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More